Overview

Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This trial is conducted globally. The purpose of this trial is to confirm the efficacy and safety of NNC 0078-0000-0007 in patients with congenital haemophilia and inhibitors.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S